Hi,
moomoo ID:NaN
Log Out
English
Back
Log in to access Online Inquiry
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
688091 Shanghai Yizhong Pharmaceutical
73.250
+3.840+5.53%
YOY
Do not show
Hide blank lines
(Q9)2022/09/30(Q6)2022/06/30(Q3)2022/03/31(FY)2021/12/31
Total operating revenue
166.32M 71.87M 34.34M 4.08M
Operating revenue
-- 166.32M -- 71.87M -- 34.34M -- 4.08M
Total operating cost
224.36% 71.91M 36.96% 18M 59.93% 9.54M -9.78% 25.05M
Operating cost
-- 11.79M -- 5.53M -- 2.32M -- 295.81K
Operating tax surcharges
2,511.81% 543.61K 1,142.76% 205.89K -41.81% 5.94K -34.23% 25.42K
Operating expense
11,941.78% 59.47M -- 11.41M -- 4.77M -- 2.32M
Administration expense
-44.89% 6.61M -28.92% 4.27M -29.42% 2.22M 23.82% 14.97M
Financial expense
-243.51% -11.26M -203.36% -5.97M -19.17% -1.23M -156.98% -5.8M
-Interest expense (Financial expense)
18.02% 491.43K -39.28% 139.54K -260.41% -93.88K 4,709.92% 588.86K
-Interest Income (Financial expense)
-217.23% -11.76M -177.17% -6.11M -4.33% -1.14M -180.20% -6.4M
Research and development
-63.29% 4.75M -72.04% 2.54M -62.10% 1.46M -26.01% 13.24M
Credit Impairment Loss
-- -1.6M -- -1.49M -- -713.31K -- -216.03K
Other net revenue
0 0 0 0
Fair value change income
1,425.36% 1.16M 1,983.89% 832.34K 63.52% 204K 2,903.53% 3.25M
Invest income
980.05% 9.54M 1,535.96% 7.1M 4,695.32% 5.32M -36.10% 2.19M
Other revenue
77.87% 1.16M -1.70% 431.38K -2.70% 219.9K 170.80% 6.47M
Operating profit
605.06% 104.67M 596.87% 60.75M 641.97% 29.83M 57.50% -9.28M
Add:Non operating Income
-99.90% 600 -- -- -- -- -- --
Less:Non operating expense
-- 1.42M -- 722.68K -- -- -- --
Total profit
613.07% 103.25M 590.96% 60.03M 641.97% 29.83M 57.52% -9.28M
Less:Income tax cost
-- -917.41K -- -953.48K -- -912.66K -- -5.28M
Net profit
FLtoP 104.17M FLtoP 60.98M FLtoP 30.74M FPtoL -4M
Net profit from continuing operation
617.63% 104.17M 598.76% 60.98M 658.55% 30.74M 81.70% -4M
Net profit of parent company owners
617.63% 104.17M 598.76% 60.98M 658.55% 30.74M 81.70% -4M
Earning per share
Basic earning per share
508.33% 0.98 486.67% 0.58 514.29% 0.29 82.14% -0.05
Diluted earning per share
508.33% 0.98 486.67% 0.58 514.29% 0.29 82.14% -0.05
Other composite income
Total composite income
617.63% 104.17M 598.76% 60.98M 658.55% 30.74M 81.70% -4M
Total composite income of parent company owners
617.63% 104.17M 598.76% 60.98M 658.55% 30.74M 81.70% -4M
Currency Unit
CNYCNYCNYCNY
Accounting Standards
CAS (2007)CAS (2007)CAS (2007)CAS (2007)

Q6, Q9, and FY are cumulative quarterly reports: Q6 is the interim report; Q9 is third quarter report; FY is the annual report.

The MOM data from the Quarterly report,MOM=(current period - last period)/last period *100%

Company Overview More
The company is committed to the development of new dosage forms of antineoplastic drugs and related products. The company is committed to the R & D and industrialization of improved new drugs for antineoplastic drugs, with high-tech talents with the background of polymer materials, pharmaceutical preparations and biology, and mastering the core and key technologies for the synthesis of nano-drug carriers and medicinal polymer excipients. The company's main research and development product is paclitaxel micelles. Paclitaxel micelle is an innovative lyophilized powder injection without polyoxyethylene castor oil and methoxy polyethylene glycol 2000-poly (lactide) copolymer as carrier.
CEO: Jingsong Zhou
Market: --
Listing Date: 09/09/2021
Hot List
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist